Compare ICHR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | CDNA |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.0B |
| IPO Year | 2016 | 2007 |
| Metric | ICHR | CDNA |
|---|---|---|
| Price | $41.43 | $17.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $40.67 | $27.33 |
| AVG Volume (30 Days) | ★ 791.9K | 539.5K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $947,652,000.00 | $48,324,000.00 |
| Revenue This Year | $18.08 | $15.37 |
| Revenue Next Year | $12.06 | $11.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 11.61 | ★ 18.93 |
| 52 Week Low | $13.15 | $10.96 |
| 52 Week High | $55.00 | $21.49 |
| Indicator | ICHR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.00 | 37.34 |
| Support Level | $15.70 | $16.74 |
| Resistance Level | $55.00 | $17.09 |
| Average True Range (ATR) | 3.51 | 0.83 |
| MACD | -1.40 | -0.21 |
| Stochastic Oscillator | 17.79 | 23.77 |
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.